Cargando…

Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals

Broadly neutralizing antibodies may protect against HIV-1 acquisition. In natural infection, only 10–30% of patients have cross-reactive neutralizing humoral immunity which may relate to viral and or host factors. To explore the role of host genetic markers in the formation of cross-reactive neutral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Euler, Zelda, van Gils, Marit J., Boeser-Nunnink, Brigitte D., Schuitemaker, Hanneke, van Manen, Daniëlle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553002/ https://www.ncbi.nlm.nih.gov/pubmed/23372753 http://dx.doi.org/10.1371/journal.pone.0054684

Ejemplares similares

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
por: van den Kerkhof, Tom L G M, et al.
Publicado: (2013)

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals
por: van den Kerkhof, TL, et al.
Publicado: (2012)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients
por: van den Kerkhof, Tom, et al.
Publicado: (2011)

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016)

Cross-reactive neutralizing activity in HIV-1 infected injecting drug users
por: Euler, Z, et al.
Publicado: (2012)

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users
por: EULER, Zelda, et al.
Publicado: (2019)

Genome-Wide Association Scan in HIV-1-Infected Individuals Identifying Variants Influencing Disease Course
por: van Manen, Daniëlle, et al.
Publicado: (2011)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics
por: van Manen, Daniëlle, et al.
Publicado: (2012)

Single Nucleotide Polymorphism in Gene Encoding Transcription Factor Prep1 Is Associated with HIV-1-Associated Dementia
por: Bol, Sebastiaan M., et al.
Publicado: (2012)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection
por: van Manen, Daniëlle, et al.
Publicado: (2008)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans
por: Malherbe, Delphine C., et al.
Publicado: (2013)

OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles
por: Schellens, IM, et al.
Publicado: (2009)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

A genetic variation in fucosyltransferase 8 accelerates HIV-1 disease progression indicating a role for N-glycan fucosylation
por: van Pul, Lisa, et al.
Publicado: (2023)

Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans
por: Huettner, Isabella, et al.
Publicado: (2022)

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies
por: Mabuka, Jenniffer M., et al.
Publicado: (2017)

Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies
por: Xiao, Xiaodong, et al.
Publicado: (2009)

Genome-Wide Association Study Identifies Single Nucleotide Polymorphism in DYRK1A Associated with Replication of HIV-1 in Monocyte-Derived Macrophages
por: Bol, Sebastiaan M., et al.
Publicado: (2011)

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
por: van der Velden, Yme U., et al.
Publicado: (2020)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Clinical significance of HIV-1 coreceptor usage
por: Schuitemaker, Hanneke, et al.
Publicado: (2011)

Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
por: van der Straten, Karlijn, et al.
Publicado: (2022)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
por: van Paassen, Pien M., et al.
Publicado: (2023)

Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
por: Williams, Wilton B., et al.
Publicado: (2021)

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody
por: Heydarchi, Behnaz, et al.
Publicado: (2022)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
por: Schommers, Philipp, et al.
Publicado: (2020)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite
por: Nogal, Bartek, et al.
Publicado: (2020)

Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies
por: Carbonetti, Sara, et al.
Publicado: (2014)

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
por: van Schooten, Jelle, et al.
Publicado: (2022)

Immunologic characteristics of HIV‐infected individuals who make broadly neutralizing antibodies
por: Borrow, Persephone, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pm642gghtbpqgovic2dnco1s8h